ConductScience.org, home

Paper8656342

Risk assessment of adverse pulmonary effects induced by adrenaline beta-receptor antagonists and rational drug dosage regimen based on receptor occupancy.

Yamada Y and 4 others. J Pharmacokinet Biopharm, 1995. Cited by 13 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Risk assessment of adverse pulmonary effects induced by adrenaline beta-receptor antagonists and rational drug dosage regimen based on receptor occupancy. Papers, record 8656342. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8656342

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Risk assessment of adverse pulmonary effects induced by adrenaline beta-receptor antagonists and rational drug dosage regimen based on receptor occupancy.
PubMed
Journal
J Pharmacokinet Biopharm
PubMed
Year
1995
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
13
iCite
Relative citation ratio, by iCite
0.46
iCite
Revised in PubMed
2019-10-24
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yamada YY
2Matsuyama KK
3Ito KK
4Sawada YY
5Iga TT

Source PubMed

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Adrenergic beta-AntagonistsMajor topic
LungMajor topic
Receptors, Adrenergic, betaMajor topic
Dose-Response Relationship, Drug
Forced Expiratory Volume
Heart Rate
Humans
Models, Biological
Nonlinear Dynamics
Risk Assessment

Source PubMed

References23

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
11,376,792Spare receptors for beta-adrenoceptor-mediated positive inotropic effects of catecholamines in the human heart.J Cardiovasc Pharmacol1992https://conductscience.org/library/papers/1376792PubMed
225,075Beta-blockers and asthma.Br Heart J1978https://conductscience.org/library/papers/25075PubMed
32,859,024Receptor binding characteristics and pharmacokinetic properties as a tool for the prediction of clinical effects of beta-blockers.Arzneimittelforschung1985https://conductscience.org/library/papers/2859024PubMed
42,892,986Beta-adrenergic blockers.Med Clin North Am1988https://conductscience.org/library/papers/2892986PubMed
62,886,244Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.Clin Pharmacokinet1987https://conductscience.org/library/papers/2886244PubMed
73,450,842Propranolol pharmacodynamic modeling using unbound and total concentrations in healthy volunteers.J Pharmacokinet Biopharm1987https://conductscience.org/library/papers/3450842PubMed
8738,350Plasma timolol levels after oral and intravenous administration.Eur J Clin Pharmacol1978https://conductscience.org/library/papers/738350PubMed
96,102,500Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function.Clin Pharmacokinet1980https://conductscience.org/library/papers/6102500PubMed
101,175,271Correlation of plasma propranolol concentration with therapeutic response in patients with angina pectoris.Circulation1975https://conductscience.org/library/papers/1175271PubMed
111,973,398[Pharmacological studies of celiprolol: I. Beta-blocking effect, intrinsic sympathomimetic activity, vasodilating and hypotensive effects].Nihon Yakurigaku Zasshi1990https://conductscience.org/library/papers/1973398PubMed
122,882,776Effect of beta-adrenoceptor blockade on exercise-induced plasma catecholamine concentrations and their dissipation profile.Br J Clin Pharmacol1987https://conductscience.org/library/papers/2882776PubMed
132,903,820Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.Drugs1988https://conductscience.org/library/papers/2903820PubMed
144,853,602Pharmacokinetics of pindolol in man.Eur J Clin Pharmacol1974https://conductscience.org/library/papers/4853602PubMed
157,328,489A pharmacokinetic analysis program (multi) for microcomputer.J Pharmacobiodyn1981https://conductscience.org/library/papers/7328489PubMed
161,094,802Combined pharmacokinetic and pharmacodynammc studies in man of the adrenergic beta1-receptor antagonist metoprolol.Acta Pharmacol Toxicol (Copenh)1975https://conductscience.org/library/papers/1094802PubMed
183,000,793Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man.Eur J Clin Pharmacol1985https://conductscience.org/library/papers/3000793PubMed
194,155,762Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man.J Pharmacokinet Biopharm1974https://conductscience.org/library/papers/4155762PubMed
202,515,395Do pharmacological methods for the quantification of agonists work when the ternary complex mechanism operates?J Theor Biol1989https://conductscience.org/library/papers/2515395PubMed
216,105,819The clinical importance of cardioselectivity and lipophilicity in beta blockers.Am Heart J1980https://conductscience.org/library/papers/6105819PubMed
227,907,513Prediction of therapeutic doses of beta-adrenergic receptor blocking agents based on quantitative structure-pharmacokinetic/pharmacodynamic relationship.Biol Pharm Bull1993https://conductscience.org/library/papers/7907513PubMed

See all 23 references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.

PMIDTitleJournalYearIn PapersSource
28,887,613Theoretical method for evaluation of therapeutic effects and adverse effects of epidermal growth factor receptor tyrosine kinase inhibitors in clinical treatment.Med Oncol2017https://conductscience.org/library/papers/28887613PubMed
28,400,472Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease.FASEB J2017https://conductscience.org/library/papers/28400472PubMed
25,510,848Evaluation of clinical bradycardiac effect and respiratory adverse effect of β-blocking agents in coronary computed tomography angiography based on theoretical analysis.Eur J Drug Metab Pharmacokinet2016https://conductscience.org/library/papers/25510848PubMed
15,180,332Ocular pharmacokinetic/ pharmacodynamic modeling for bunazosin after instillation into rabbits.Pharm Res2004https://conductscience.org/library/papers/15180332PubMed

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
BDKRB1623PubTator's text mininghttps://conductscience.org/library/genes/623NCBI Gene
BDKRB2624PubTator's text mininghttps://conductscience.org/library/genes/624NCBI Gene
MS4A1931PubTator's text mininghttps://conductscience.org/library/genes/931NCBI Gene

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8656342

GET https://conductscience.org/api/papers/v1/8656342/references?page=2